Relationship of response and survival in patients with relapsed and refractory multiple myeloma treated with pomalidomide plus low-dose dexamethasone in the MM-003 trial randomized phase III trial (NIMBUS). Issue 12 (1st December 2016)

• Record Type: Journal Article
• Authors: Moreau, Philippe; Weisel, Katja C.; Song, Kevin W.; Gibson, Craig J.; Saunders, Owain; Sternas, Lars Axel; Hong, Kevin; Zaki, Mohamed H.; Dimopoulos, Meletios A.
• Is Part Of: Leukemia & lymphoma. Volume 57:Issue 12(2016:Dec.)
• Page Start: 2839
• Page End: 2847
• Publication Date: 2016-12-01
• Subjects: MM-003 -- multiple myeloma -- pomalidomide; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2016.1180685
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: Relapsed/refractory multiple myeloma (RRMM) patients have poor overall survival (OS). Pomalidomide plus low-dose dexamethasone (POM + LoDEX) significantly extends OS in RRMM vs. high-dose dexamethasone. Survival of patients with stable disease (SD) was compared to patients with progressive disease (PD) or ≥ partial response (≥PR) at cycles (C) 3, 5, and 7. Among 302 patients randomized to POM + LoDEX, at C3 19.2% achieved ≥ PR, 38.4% SD, and 14.6% PD. Patients with SD at C3 (17.4%) and C5 (13.6%) showed improved responses at C7. Median OS from randomization by response at C3 was 22.4 months for ≥ PR ( n = 58, HR 0.66; 95% CI 0.40–1.08, p = 0.0976 vs. SD), 16.2 months for SD ( n = 116), and 6.3 months for PD ( n = 44, HR 3.43; 95% CI 2.23–5.27, p < 0.0001 vs. SD). Similar patterns were observed for C5 and C7. Results show that POM + LoDEX should be a standard treatment after lenalidomide and bortezomib, including in SD patients.